Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-04

Study Completion Date

2024-01-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies how well cycling works in preventing colorectal cancer in participants with Lynch syndrome. Exercise such as cycling may reduce colorectal cancer risk in participants with Lynch syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lifestyle Change for Better Health

NCT03286699

Bladder Cancer Telomere Shortening Colorectal Adenoma

TERMINATED NA

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

NCT03284346

Cancer Survivor No Evidence of Disease Obesity +13 more

TERMINATED NA

Researching the Effect of Exercise on Cancer

NCT04589468

Breast Cancer Prostate Cancer Colorectal Cancer +9 more

ACTIVE_NOT_RECRUITING NA

Exercise and Mortality in Middle-Aged and Older Adults

NCT07224659

Overall Survival (All-cause Mortality)

NOT_YET_RECRUITING

Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer

NCT05789433

Colonic Neoplasms Rectal Neoplasms

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To assess the feasibility of a 12-month exercise cycling intervention among Lynch syndrome (LS) patients.

SECONDARY OBJECTIVES:

I. To assess the effect size of exercise on circulating biomarkers as well as regulation of genomic, transcriptomic, and immunologic biomarkers in normal intestinal mucosa of LS patients.

OUTLINE: Participants are assigned to 1 of 2 groups.

GROUP I: Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.

GROUP II: Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.

After completion of study interventions, participants are followed up at 30 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High-Frequency Microsatellite Instability Mismatch Repair Gene Mutation Mutation-Negative Lynch Syndrome Mutation-Positive Lynch Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I (FITBIT, cycling)

Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.

Group Type EXPERIMENTAL

Exercise Intervention

Intervention Type BEHAVIORAL

Complete cycling classes

Monitoring Device

Intervention Type DEVICE

Wear Fitbit

Questionnaire Administration

Intervention Type OTHER

Complete questionnaire

Group II (FITBIT, information)

Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.

Group Type ACTIVE_COMPARATOR

Informational Intervention

Intervention Type OTHER

Receive information about exercise guidelines

Monitoring Device

Intervention Type DEVICE

Wear Fitbit

Questionnaire Administration

Intervention Type OTHER

Complete questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise Intervention

Complete cycling classes

Intervention Type BEHAVIORAL

Informational Intervention

Receive information about exercise guidelines

Intervention Type OTHER

Monitoring Device

Wear Fitbit

Intervention Type DEVICE

Questionnaire Administration

Complete questionnaire

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Monitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must have Lynch syndrome defined as meeting any of the following: (1) Mutation-positive Lynch syndrome: carriers or obligate carriers (by pedigree) of a pathogenic mutation in one of the deoxyribonucleic acid (DNA) mismatch repair (MMR) genes (i.e. MLH1, MSH2/EPCAM, MSH6, or PMS2) or (2) Mutation-negative Lynch syndrome: patients with a personal history of a non-sporadic MMR deficient premalignant lesion (i.e. polyp) or a non sporadic MMR deficient malignant tumor (where non-sporadic MMR deficient is defined by: microsatellite instability high by either immunohistochemistry or microsatellite instability (MSI) testing or both, but no evidence of MLH1 promoter methylation in cases with loss of both MLH1 and PMS2, and/or no evidence of BRAF mutation in cases with loss of both MLH1 and PMS2) but germline MMR genetic testing showed either a variant of unknown significance or mutation negative result or had declined germline MMR genetic testing.
* Participants must not have evidence of active/recurrent malignant disease for a minimum of 6 months.
* Participants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation).
* Participants must have endoscopically accessible distal colon and/or rectal mucosa (i.e. participants must have at least part of the descending/sigmoid colon and/or rectum intact).
* Participants must consent to two standard of care lower gastro-intestinal GI endoscopy (flexible sigmoidoscopy or colonoscopy) with biopsies that will be 12 months (+/-21 days) apart.
* Ability to understand and the willingness to sign a written informed consent document.
* Must have normal cardiopulmonary exercise test prior to exercise participation.

Exclusion Criteria

* Individuals who are status post total proctocolectomy (i.e. removal of all colon and rectum).
* Individuals with history of myocardial infarction, stroke, coronary-artery bypass draft, invasive coronary revascularization, arrhythmia requiring treatment such as atrial fibrillation, congestive heart failure, peripheral vascular disease, pulmonary embolism, or deep venous thrombosis.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Individuals with a history of diabetes, hypertension, or have smoked cigarettes in the last 12 months.
* Individuals who are unable to participate in cycling due to musculoskeletal limitations.
* Individuals who are unable to identify cycling classes in their community for exercise.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No